← boardnext 2026-09next 2026-11
TYRA
Tyra Biosciences, Incdistress 3/10 · well-funded / low risk$29.72-3%today-25% from 52w high
Oncology 1
Lead: Solid Tumor
Revenue
pre-revenue
Liquidity
$85M
Runway
0.8 yrs
Shares 1y
+12%
Price & events
-3.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
-6.0%
1W
-1.1%
1M
-19.0%
3M
-2.1%
6M
+174.9%
1Y
+36.3%
2Y
—
5Y
+14.3%
All
Overview
- Market Cap
- $1.77B
- Volume
- 28.33K
- 52 Week Range
- $10.10 – $39.61
- Total Shares
- 59.47M
- Float Shares
- 30.92M
- Short %
- 37.07%
- % Held by Insiders
- 2.86%
- % Held by Institutions
- 111.66%
- RVOL
- 0.03x
- Beta
- 0.76
Pipeline stages · 2 programs
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phas
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg, Dabogratinib (TYRA-300) TBD
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-01 | Phase 1 | Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phas | Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma | 40 | recruiting |
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 1/2 | TYRA-300 | Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma | — | active not recruiting |
| 2028-01 Estimated 50% readout ~2028-01-31 | Phase 1 | TYRA-430 | Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma | — | recruiting |
| 2028-02 Estimated 50% readout ~2028-03-17 | Phase 2 | TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose TBD | Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions | — | recruiting |
| 2030-01 Estimated 50% readout ~2030-02-15 | Phase 2 | TYRA-300 0.125 mg/kg, TYRA-300 0.25 mg/kg, TYRA-300 0.375 mg/kg | Achondroplasia | — | recruiting |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2030-10 Estimated 50% readout ~2030-11-15 | Phase 2 | Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg, Dabogratinib (TYRA-300) TBD | Low Grade Upper Tract Urothelial Carcinoma | — | recruiting |
| 2025-05 | Phase 1 | TYRA-300-B01 | Healthy | 60 | active not recruiting |
Catalyst news & presentations · 10
- second half of 2026Guided 55%readoutPhase 2dabogratinib · Initial results from safety sentinel cohort of BEACH301 studySEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 2TYRA-300 · initial three-month complete response dataSEC 8-K
- 2026-03-04partnershipAgreed to issue 4M shares at $31.50 each for gross proceeds of $126MSEC 8-K
- second half of 2025trial initiationsecondaryPhase 2TYRA-300 · expects first child dosing in BEACH301 Phase 2 studySEC 8-K
- 2025-06-30trial initiationsecondaryPhase 2TYRA-300 · first patient dosed in SURF302 Phase 2 studySEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 2TYRA-300 · First child dosed in BEACH301 trialSEC 8-K
- by year-end 2024regulatory submissionFiled (NDA/BLA)TYRA-300 · Plan to submit IND for Phase 2 study in NMIBCSEC 8-K
- 2024-10-28fda agreementTYRA-300 · FDA allowed IND to proceed for Phase 2 trial in achondroplasiaSEC 8-K
- October 25, 2024, 8:00 a.m. ETconferencedata presentationsecondaryPhase 1/2TYRA-300 · Interim clinical results from SURF301 Phase 1/2 studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $52 (+75% upside) · 12 analysts
- 2026-06-17Jones TradingBuy
- 2026-06-10B of A SecuritiesBuy
- 2026-05-19Wolfe ResearchPeer Perform
- 2026-05-14HC Wainwright & Co.Buy
- 2026-04-15GuggenheimBuy
- 2026-04-06Canaccord GenuityBuy
Competitors — Solid Tumor
- NVSEFNOVARTIS AG$292.0B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- INCYINCYTE CORP$23.1B · D0
- ERASErasca, Inc.$5.9B · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- XLOXilio Therapeutics, Inc.$50M · D1
- APREAprea Therapeutics, Inc.$8M · D6
Recent news
- 2026-07-21Behavioral Patterns of TYRA and Institutional Flows - Stock Traders Daily
- 2026-07-21Tyra Biosciences (TYRA) Bank of America Global Healthcare Conference 2026 Summary - Quartr
- 2026-07-11Price to earnings forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
- 2026-07-10Behavioral Patterns of TYRA and Institutional Flows - Stock Traders Daily
- 2026-07-08Price to sales forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
- 2026-07-08Tyra Biosciences Inc. (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline Progress Drives Positive Sentiment - Post-Earnings Drift - dars.gov.et
- 2026-06-30Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Insider Monkey
- 2026-06-30Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.